BioSpace News Archive

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2022.

Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced the appointment of Joshua Reed as Chief Financial Officer, effective May 23, 2022.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) will release its first-quarter financial results on Tuesday, May 10, 2022. Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update.

CytoSorbents Corporation announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb™-ATR Antithrombotic Removal System for intraoperative removal of apixaban and rivaroxaban during cardiothoracic surgery.

BeiGene, Ltd. announced the groundbreaking of its flagship U.S. manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J.

Forma Therapeutics Holdings, Inc. today announced that it will release first quarter 2022 financial results Friday, May 6, 2022.

Ictero Medical, Inc. raised an oversubscribed $6M Series A financing led by MedTex Ventures, S3 Ventures, and an undisclosed strategic investor.

Castle Biosciences, Inc. today announced that its current U.S. Federal Supply Schedule (FSS) contract with the Veterans Health Administration (VHA) has been expanded to include coverage for the Company’s entire skin cancer test portfolio, effective as of April 15, 2022.

Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022, which reflect robust in-line product growth, increased adoption of new product portfolio and strong commercial execution.

TFF Pharmaceuticals, Inc. today announced that it will release its financial results and business update for the first quarter of 2022 on Wednesday, May 11, 2022, after the close of the U.S. financial markets.